Catena Biosciences

Catena Biosciences is a private, pre-clinical biotech pioneering a novel protein conjugation platform to overcome key limitations of current antibody-drug conjugates (ADCs). Its core innovation is the CysTyr platform, which utilizes a proprietary enzyme to form a stable C-Y Bond between natural amino acids, enabling the attachment of multiple, diverse payloads (e.g., toxins, nucleic acids, cytokines) to a single antibody with precise control. With an early pipeline focused on dual-payload ADCs for solid tumors like TROP2-expressing cancers, Catena aims to demonstrate superior efficacy and reduced off-target toxicity compared to standard ADCs. The company is at an early stage, building its leadership team and advancing its platform toward proof-of-concept in vivo data.

CysTyr conjugation platform utilizing proprietary Catenase enzyme to form stable C-Y Bond between cysteine and tyrosine residues, enabling creation of Multi-Payload Conjugates (MPCs) with diverse payloads of any size/complexity.

Catena competes in the crowded next-generation ADC space against companies developing site-specific conjugation (e.g., Abzena, Synaffix), novel linkers, and new payload classes. Key differentiators are the claimed ability to attach multiple, diverse payload types with high stability. They face competition from both platform companies and large pharma with internal ADC efforts.